Pascua, Lourdes B.
HRN: 26-46-75 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/08/2025
CO-AMOXICLAV 625MG (TAB)
01/08/2025
01/12/2025
ORAL
625mg
TID
CAP MR
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes